Blood Cancer Talks

In this episode, we deeply dive into the management of newly diagnosed younger adults with AML with Dr. Eytan Stein from Memorial Sloan Kettering Cancer Center and discuss key clinical trials that have shaped the current treatment paradigm. This is a gem!

Show Notes

Study showing the time from diagnosis of AML to the start of intensive treatment indicate that a treatment delay has no negative prognostic impact.
RATIFY clinical trial showing the addition of midostaurin (FLT3 inhibitor) to 7+3 chemotherapy for AML
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the European LeukemiaNet (ELN)
ASH 2022 abstract presenting Daunorubicin 60 Vs 90 mg/m2
ALFA-0701. The addition of gemtuzumab ozogamicin, an anti-CD33 antibody conjugate, to the standard treatment for patients with acute myeloid leukemia
Quizartinib data presented at EHA 2022
International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemias
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk